SPY749.60−0.63%QQQ674.25−0.83%BTC/USD67,135.37−1.61%DIA521.21−0.37%GLD355.70+0.07%TLT79.42+0.05%

Xencor Inc

XNCRNASDAQ

Trade with Public

$37.09

-1.04-2.73%

At close: Nov 13, 4:00 PM EST

$37.09

N/A

After Hours: 4:00 PM EST

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Xencor (XNCR) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Xencor (XNCR) stock.

Analyst Consensus — 14 Analysts

1S.Buy

10Buy

2Hold

1Sell

# Analysts14

Latest Upgrades and Downgrades for Xencor Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Cantor Fitzgerald	Steve Seedhouse	Maintained	Overweight	$70
—	Truist Securities	Gregory Renza	PT Raise	Buy	$29→$40
—	RBC Capital	Leonid Timashev	PT Raise	Outperform	$20→$43
—	Wells Fargo	Derek Archila	PT Raise	Overweight	$30→$44
—	Wedbush	David Nierengarten	PT Raise	Outperform	$30→$45
—	Wedbush	David Nierengarten	Maintained	Outperform	$30
—	Truist Securities	Gregory Renza	PT Raise	Buy	$27→$29
—	B of A Securities	Alec Stranahan	PT Raise	Neutral	$20→$26
—	Barclays	Etzer Darout	PT Raise	Overweight	$27→$35
—	JP Morgan	Brian Cheng	PT Raise	Neutral	$14→$21
—	Raymond James	Sean McCutcheon	PT Raise	Strong Buy	$40→$46
—	RBC Capital	Leonid Timashev	PT Raise	Outperform	$19→$20
—	Wedbush	David Nierengarten	PT Raise	Outperform	$26→$30
—	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$43→$44
—	Wedbush	David Nierengarten	Maintained	Outperform	$26
—	Truist Securities	Gregory Renza	PT Cut	Buy	$29→$27
—	JP Morgan	Brian Cheng	PT Raise	Neutral	$13→$14
—	JP Morgan	Brian Cheng	Downgrade	Overweight→Neutral	$18→$13
—	Barclays	Etzer Darout	PT Raise	Overweight	$26→$27
—	Barclays	Etzer Darout	PT Raise	Overweight	$23→$26

Xencor Inc

Xencor (XNCR) Stock Price Target 2026

Latest Upgrades and Downgrades for Xencor Stock

Xencor (XNCR) Stock Price Target 2026

Latest Upgrades and Downgrades for Xencor Stock

Analyst Ratings News

PRO
Cantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price Target

PRO
Truist Securities Maintains Buy on Xencor, Raises Price Target to $40

PRO
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43

PRO
Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44

PRO
Wedbush Maintains Outperform on Xencor, Raises Price Target to $45

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Cantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price Target

PRO
Truist Securities Maintains Buy on Xencor, Raises Price Target to $40

PRO
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43

PRO
Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44

PRO
Wedbush Maintains Outperform on Xencor, Raises Price Target to $45

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

Xencor Inc

Xencor (XNCR) Stock Price Target 2026

Latest Upgrades and Downgrades for Xencor Stock

Xencor (XNCR) Stock Price Target 2026

Latest Upgrades and Downgrades for Xencor Stock

Analyst Ratings News

PROCantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price Target

PROTruist Securities Maintains Buy on Xencor, Raises Price Target to $40

PRORBC Capital Maintains Outperform on Xencor, Raises Price Target to $43

PROWells Fargo Maintains Overweight on Xencor, Raises Price Target to $44

PROWedbush Maintains Outperform on Xencor, Raises Price Target to $45

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

People Also Watch

People Also Watch

Analyst Ratings News

PROCantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price Target

PROTruist Securities Maintains Buy on Xencor, Raises Price Target to $40

PRORBC Capital Maintains Outperform on Xencor, Raises Price Target to $43

PROWells Fargo Maintains Overweight on Xencor, Raises Price Target to $44

PROWedbush Maintains Outperform on Xencor, Raises Price Target to $45

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

PRO
Cantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price Target

PRO
Truist Securities Maintains Buy on Xencor, Raises Price Target to $40

PRO
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43

PRO
Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44

PRO
Wedbush Maintains Outperform on Xencor, Raises Price Target to $45

PRO
Cantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price Target

PRO
Truist Securities Maintains Buy on Xencor, Raises Price Target to $40

PRO
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43

PRO
Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44

PRO
Wedbush Maintains Outperform on Xencor, Raises Price Target to $45